Skip to content
HowShorted

2seventy bio, Inc. short interest in 2023

In 2023, 2seventy bio, Inc.'s disclosed short interest ran from 9.85% of shares outstanding on 13 Jan 2023 to 12.74% on 29 Dec 2023, a change of +2.89 percentage points. The year's high was 30.15% on 29 Sep 2023 and its low 9.85% on 13 Jan 2023, averaging 17.35% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.59 days on 14 Jul 2023. Full history: 2seventy bio, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for 2seventy bio, Inc. in 2023

2023 in figures

Start of year
9.85% (13 Jan 2023)
End of year
12.74% (29 Dec 2023)
Change
+2.89 pp
High
30.15% (29 Sep 2023)
Low
9.85% (13 Jan 2023)
Average
17.35%
Highest days to cover
25.59 (14 Jul 2023)
SEC filings marked
13

Every report in 2023

2seventy bio, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20239.85%5.50results (8-K)
31 Jan 202310.74%7.00
15 Feb 202313.13%5.94results (8-K)
28 Feb 202315.44%11.30
15 Mar 202313.51%5.04
31 Mar 202315.26%8.0910-K filed, results (8-K)
14 Apr 202315.29%10.10
28 Apr 202315.79%10.34results (8-K)
15 May 202315.34%8.08results (8-K), 10-Q filed
31 May 202315.11%10.58
15 Jun 202314.38%9.12
30 Jun 202316.63%9.00
14 Jul 202317.83%25.59
31 Jul 202316.44%8.26results (8-K)
15 Aug 202314.02%4.1610-Q filed, results (8-K)
31 Aug 202317.22%8.33
15 Sep 202321.20%5.27
29 Sep 202330.15%9.67
13 Oct 202329.28%10.87
31 Oct 202322.40%4.52results (8-K)
15 Nov 202324.31%10.1810-Q filed, results (8-K)
30 Nov 202323.60%4.57
15 Dec 202316.80%3.21
29 Dec 202312.74%4.64

See also: 2seventy bio, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.